Articoli con mandati relativi all'accesso pubblico - Eva M LonnUlteriori informazioni
Non disponibili pubblicamente: 11
The relationship between trimethylamine-N-oxide and prevalent cardiovascular disease in a multiethnic population living in Canada
A Mente, K Chalcraft, H Ak, AD Davis, E Lonn, R Miller, MA Potter, S Yusuf, ...
Canadian Journal of Cardiology 31 (9), 1189-1194, 2015
Mandati: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada
Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia
SD McDonald, J Ray, K Teo, H Jung, O Salehian, S Yusuf, E Lonn
Atherosclerosis 229 (1), 234-239, 2013
Mandati: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada
Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors
AC Philpott, E Lonn, LM Title, S Verma, J Buithieu, F Charbonneau, ...
The American journal of cardiology 103 (11), 1610-1615, 2009
Mandati: Canadian Institutes of Health Research
Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics
E Lonn, J Bosch, J Pogue, A Avezum, I Chazova, A Dans, R Diaz, ...
Canadian Journal of Cardiology 32 (3), 311-318, 2016
Mandati: Canadian Institutes of Health Research
Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia
SD McDonald, S Yusuf, MW Walsh, E Lonn, K Teo, SS Anand, J Pogue, ...
Diabetic Medicine 30 (1), e1-e7, 2013
Mandati: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada
Long-term effects of statins, blood pressure-lowering, and both on erectile function in persons at intermediate risk for cardiovascular disease: a substudy of the Heart …
P Joseph, E Lonn, J Bosch, P Lopez, J Zhu, M Keltai, A Dans, C Reid, ...
Canadian Journal of Cardiology 34 (1), 38-44, 2018
Mandati: Canadian Institutes of Health Research
The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials
S Yusuf, E Lonn
JAMA cardiology 1 (8), 857-858, 2016
Mandati: Canadian Institutes of Health Research
Association of apolipoproteins B and A-1 with markers of vascular health or cardiovascular events
YM Zhu, S Verma, M Fung, MJ McQueen, TJ Anderson, EM Lonn
Canadian Journal of Cardiology 33 (10), 1305-1311, 2017
Mandati: Canadian Institutes of Health Research
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study
P Pais, H Jung, A Dans, J Zhu, L Liu, D Kamath, J Bosch, E Lonn, S Yusuf
European Journal of Preventive Cardiology 26 (7), 681-697, 2019
Mandati: Canadian Institutes of Health Research
The cost implication of primary prevention in the HOPE 3 trial
A Lamy, E Lonn, W Tong, B Swaminathan, H Jung, A Gafni, J Bosch, ...
European Heart Journal-Quality of Care and Clinical Outcomes 5 (3), 266-271, 2019
Mandati: Canadian Institutes of Health Research
Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke
M Boehm, H Schumacher, KK Teo, EM Lonn, L Lauder, G Mancia, ...
Journal of Hypertension 39 (8), 1602-1610, 2021
Mandati: German Research Foundation, UK Medical Research Council, National Institute …
Disponibili pubblicamente: 74
Heart disease and stroke statistics—2010 update: a report from the American Heart Association
Writing Group Members, D Lloyd-Jones, RJ Adams, TM Brown, ...
Circulation 121 (7), e46-e215, 2010
Mandati: US National Institutes of Health, Canadian Institutes of Health Research
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ...
New England Journal of Medicine 374 (21), 2021-2031, 2016
Mandati: Canadian Institutes of Health Research
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ...
The Lancet 391 (10117), 219-229, 2018
Mandati: American Heart Association
Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ...
New England Journal of Medicine 374 (21), 2009-2020, 2016
Mandati: Canadian Institutes of Health Research
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ...
The Lancet 393 (10170), 407-415, 2019
Mandati: National Health and Medical Research Council, Australia, British Heart …
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project
S Blankenberg, T Zeller, O Saarela, AS Havulinna, F Kee, ...
Circulation 121 (22), 2388-2397, 2010
Mandati: Canadian Institutes of Health Research, Heart and Stroke Foundation of …
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 …
R Clarke, J Halsey, S Lewington, E Lonn, J Armitage, JAE Manson, ...
Archives of internal medicine 170 (18), 1622-1631, 2010
Mandati: US National Institutes of Health, British Heart Foundation, Cancer Research UK
Blood-pressure and cholesterol lowering in persons without cardiovascular disease
S Yusuf, E Lonn, P Pais, J Bosch, P Lopez-Jaramillo, J Zhu, D Xavier, ...
New England Journal of Medicine 374 (21), 2032-2043, 2016
Mandati: Canadian Institutes of Health Research
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals
SE Vollset, R Clarke, S Lewington, M Ebbing, J Halsey, E Lonn, ...
The Lancet 381 (9871), 1029-1036, 2013
Mandati: US National Institutes of Health, British Heart Foundation, Cancer Research UK
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software